Results 151 to 160 of about 38,595 (290)
Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis
Obesity Reviews, EarlyView.ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim +4 more
wiley +1 more source
GLP‐1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Elaine J. Ma +9 more
wiley +1 more source
Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.ABSTRACT Background Diabetes and its risk factors are embedded in a complex multilevel ecology. Upstream factors (i.e., ‘forcing factors’ that refer to fundamental population‐based social, economic, and political structures shaping health outcomes long before disease develops) and downstream risk factors (i.e., the individual‐level characteristics and ...
Nicolaas P. Pronk +5 more
wiley +1 more source
Aims: Combining insulin with a glucagon-like peptide-1 receptor agonist (GLP-1RA) to treat type 2 diabetes (T2D) is common. While many studies have investigated concomitant therapy with basal insulin+GLP-1RA, few have reported on premixed insulin+GLP-1RA.
Davies, Melanie
core +1 more source
Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra +7 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2015 Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton, NJ,
MacConell L +4 more
doaj
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.Tendon injuries in diabetes heal poorly, with unclear drivers of extracellular matrix disruption and altered mechanics. This narrative review synthesizes in vitro, animal, and human studies, highlighting serum advanced glycation end products as potential systemic contributors.
Eric J. Gutierrez +3 more
wiley +1 more source
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 7, July 2026.ABSTRACT Background Obesity, diabetes, and cardiovascular disease often co‐exist in people with chronic kidney disease, placing them at high risk for adverse health outcomes. Availability of highly effective medications that span cardiovascular‐kidney‐metabolic (CKM) conditions, but limited uptake in real world settings, calls for a new transformative ...
Omolayo Umaru +9 more
wiley +1 more source
GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation? [PDF]
CirculationInoue K, Kazi DS.
europepmc +1 more source